# Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome

> **NCT04213274** · PHASE2 · WITHDRAWN · sponsor: **R-Pharm Overseas, Inc.**

## Conditions studied

- Schnitzler Syndrome
- Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)

## Interventions

- **BIOLOGICAL:** 80 mg RPH-104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04213274
- **Lead sponsor:** R-Pharm Overseas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-05
- **Primary completion:** 2023-08
- **Final completion:** 2024-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** due to the decision of company Top management
- **Last updated:** 2024-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04213274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04213274, "Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04213274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*